Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Compugen Ltd (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CGEN
Nasdaq
8731
https://cgen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Compugen Ltd (USA)
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
- Mar 12th, 2024 4:00 pm
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
- Mar 11th, 2024 11:00 am
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 2:41 pm
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
- Mar 6th, 2024 12:00 pm
Compugen Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 6th, 2024 10:29 am
Compugen Reports Fourth Quarter and Full Year 2023 Results
- Mar 5th, 2024 12:00 pm
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
- Feb 29th, 2024 1:58 pm
ACM Research (ACMR) to Report Q4 Earnings: What's in Store?
- Feb 27th, 2024 1:57 pm
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
- Feb 26th, 2024 12:00 pm
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
- Feb 21st, 2024 5:00 pm
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
- Feb 20th, 2024 12:00 pm
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
- Feb 15th, 2024 12:00 pm
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
- Jan 8th, 2024 12:05 pm
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Jan 8th, 2024 12:00 pm
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
- Dec 21st, 2023 4:39 pm
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
- Dec 20th, 2023 3:33 pm
Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
- Dec 20th, 2023 10:27 am
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
- Dec 19th, 2023 12:10 pm
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
- Dec 19th, 2023 12:05 pm
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
- Dec 19th, 2023 12:00 pm
Scroll